BR112022017308A2 - Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral - Google Patents
Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviralInfo
- Publication number
- BR112022017308A2 BR112022017308A2 BR112022017308A BR112022017308A BR112022017308A2 BR 112022017308 A2 BR112022017308 A2 BR 112022017308A2 BR 112022017308 A BR112022017308 A BR 112022017308A BR 112022017308 A BR112022017308 A BR 112022017308A BR 112022017308 A2 BR112022017308 A2 BR 112022017308A2
- Authority
- BR
- Brazil
- Prior art keywords
- bacterial strains
- oral use
- probiotic bacterial
- composition including
- antiviral action
- Prior art date
Links
- 102000010445 Lactoferrin Human genes 0.000 title abstract 3
- 108010063045 Lactoferrin Proteins 0.000 title abstract 3
- 230000001580 bacterial effect Effects 0.000 title abstract 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title abstract 3
- 229940078795 lactoferrin Drugs 0.000 title abstract 3
- 235000021242 lactoferrin Nutrition 0.000 title abstract 3
- 239000006041 probiotic Substances 0.000 title abstract 3
- 230000000529 probiotic effect Effects 0.000 title abstract 3
- 235000018291 probiotics Nutrition 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- 241000315672 SARS coronavirus Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIÇÃO QUE COMPREENDE LACTOFERRINA E CEPAS BACTERIANAS PROBIÓTICAS PARA USO ORAL COM AÇÃO ANTIVIRAL. A presente invenção refere-se a uma composição que compreende lactoferrina e, opcionalmente, cepas bacterianas probióticas e/ou N-acetilcisteína e/ou ácido hialurônico para uso oral como agente antiviral, de preferência para uso no tratamento de infecções virais do sistema respiratório por um SARS-coronavírus (por exemplo, COVID-19).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000005011A IT202000005011A1 (it) | 2020-03-09 | 2020-03-09 | Lattoferrina per uso orale ad azione antivirale |
| PCT/IB2021/051959 WO2021181276A1 (en) | 2020-03-09 | 2021-03-09 | Composition comprising lactoferrin and probiotic bacterial strains for oral use with antiviral action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017308A2 true BR112022017308A2 (pt) | 2022-10-11 |
Family
ID=70804945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017243A BR112022017243A2 (pt) | 2020-03-09 | 2020-10-15 | Lactoferrina para uso oral com ação antiviral |
| BR112022017308A BR112022017308A2 (pt) | 2020-03-09 | 2021-03-09 | Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017243A BR112022017243A2 (pt) | 2020-03-09 | 2020-10-15 | Lactoferrina para uso oral com ação antiviral |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230080695A1 (pt) |
| EP (2) | EP4117711A2 (pt) |
| JP (2) | JP2023516461A (pt) |
| CN (2) | CN115697382A (pt) |
| AU (2) | AU2020292850A1 (pt) |
| BR (2) | BR112022017243A2 (pt) |
| CA (2) | CA3174706A1 (pt) |
| IL (2) | IL295528A (pt) |
| IT (1) | IT202000005011A1 (pt) |
| MX (2) | MX2022010874A (pt) |
| WO (2) | WO2020250209A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2593452A (en) * | 2020-03-16 | 2021-09-29 | Mead Johnson Nutrition Co | Use of lactoferrin |
| IT202000009430A1 (it) * | 2020-04-29 | 2021-10-29 | Tdc Tech Dedicated To Care Srl | Composizione per la prevenzione e/o il trattamento delle infezioni delle vie respiratorie |
| US20230149515A1 (en) * | 2020-04-29 | 2023-05-18 | The Regents Of The University Of Michigan | Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof |
| EP4285920A4 (en) * | 2021-02-01 | 2024-10-23 | Dermopartners S L | COMPOSITION FOR USE AS ANTIVIRAL AGENT IN THE FORM OF NASAL DROPS AND IN NEBULIZERS |
| WO2022172523A1 (ja) * | 2021-02-09 | 2022-08-18 | 森永乳業株式会社 | プラズマサイトイド樹状細胞活性化用組成物 |
| WO2024018374A1 (en) | 2022-07-20 | 2024-01-25 | Frimline Private Limited | A pharmaceutical composition providing mucolytic effect |
| WO2024149375A1 (en) * | 2023-01-13 | 2024-07-18 | The Chinese University Of Hong Kong | Synbiotic compositions for improving immunity and for treating atopic dermatitis |
| CN116509821A (zh) * | 2023-03-07 | 2023-08-01 | 广州见华医学科技有限公司 | 一种乳铁蛋白贴剂在制备用于冠状病毒引起感染性疾病治疗药物中的用途 |
| CN117018169A (zh) * | 2023-10-07 | 2023-11-10 | 广州菲勒生物科技有限公司 | 一种预防呼吸道病毒感染的营养组合物制剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06316529A (ja) * | 1991-12-03 | 1994-11-15 | Imuno Japan:Kk | レンチウイルス感染に随伴する日和見感染症の治療予 防用医薬組成物 |
| JPH1171301A (ja) * | 1997-08-29 | 1999-03-16 | Morinaga Milk Ind Co Ltd | 抗動物感染性ウイルス剤及び飼料 |
| AU4486501A (en) * | 2000-03-27 | 2001-10-08 | Pharming Intellectual Property Bv | High dosage parenteral administration of lactoferrin |
| JP2004083487A (ja) * | 2002-08-27 | 2004-03-18 | Morinaga Milk Ind Co Ltd | 抗ウイルス組成物及びウイルス感染症予防・治療用組成物 |
| WO2006047744A2 (en) * | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| JP2011510684A (ja) * | 2008-02-06 | 2011-04-07 | ザ プロクター アンド ギャンブル カンパニー | 呼吸器状態に対する免疫反応を強化するための組成物、方法、及びキット |
| IT1392672B1 (it) * | 2009-01-12 | 2012-03-16 | Wyeth Consumer Healthcare S P A | Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina |
| KR101235561B1 (ko) * | 2010-12-09 | 2013-03-21 | 주식회사 제일바이오 | 항바이러스 및 항균 활성을 갖는 락토바실러스 플란타룸 ｃｌｐ-1 균주 및 이를 포함하는 생균제 |
| EP3419629A4 (en) * | 2016-02-25 | 2019-10-30 | Applied Biological Laboratories, Inc. | COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES |
| WO2018191073A1 (en) * | 2017-04-12 | 2018-10-18 | The Uab Research Foundation | Inhaled respiratory probiotics for lung diseases of infancy, childhood and adulthood |
| US11376311B2 (en) * | 2017-11-02 | 2022-07-05 | Colorado Seminary, Owner and Operator of University of Denver | Methods of treating microbial infection and inflammation |
-
2020
- 2020-03-09 IT IT102020000005011A patent/IT202000005011A1/it unknown
- 2020-10-15 JP JP2022554336A patent/JP2023516461A/ja active Pending
- 2020-10-15 CA CA3174706A patent/CA3174706A1/en active Pending
- 2020-10-15 EP EP20796654.0A patent/EP4117711A2/en active Pending
- 2020-10-15 WO PCT/IB2020/059695 patent/WO2020250209A2/en active Application Filing
- 2020-10-15 US US17/798,050 patent/US20230080695A1/en active Pending
- 2020-10-15 AU AU2020292850A patent/AU2020292850A1/en active Pending
- 2020-10-15 IL IL295528A patent/IL295528A/en unknown
- 2020-10-15 BR BR112022017243A patent/BR112022017243A2/pt unknown
- 2020-10-15 MX MX2022010874A patent/MX2022010874A/es unknown
- 2020-10-15 CN CN202080098096.3A patent/CN115697382A/zh not_active Withdrawn
-
2021
- 2021-03-09 CA CA3174733A patent/CA3174733A1/en active Pending
- 2021-03-09 MX MX2022010870A patent/MX2022010870A/es unknown
- 2021-03-09 US US17/798,052 patent/US20230330164A1/en active Pending
- 2021-03-09 AU AU2021235546A patent/AU2021235546A1/en active Pending
- 2021-03-09 CN CN202180019922.5A patent/CN115279397A/zh not_active Withdrawn
- 2021-03-09 WO PCT/IB2021/051959 patent/WO2021181276A1/en active Application Filing
- 2021-03-09 IL IL295525A patent/IL295525A/en unknown
- 2021-03-09 BR BR112022017308A patent/BR112022017308A2/pt unknown
- 2021-03-09 JP JP2022554327A patent/JP2023517327A/ja active Pending
- 2021-03-09 EP EP21716547.1A patent/EP4117710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020292850A1 (en) | 2022-09-08 |
| EP4117711A2 (en) | 2023-01-18 |
| WO2020250209A3 (en) | 2021-02-18 |
| CN115279397A (zh) | 2022-11-01 |
| CA3174706A1 (en) | 2020-12-17 |
| CN115697382A (zh) | 2023-02-03 |
| IL295525A (en) | 2022-10-01 |
| WO2021181276A1 (en) | 2021-09-16 |
| JP2023517327A (ja) | 2023-04-25 |
| US20230330164A1 (en) | 2023-10-19 |
| MX2022010870A (es) | 2023-01-04 |
| WO2020250209A2 (en) | 2020-12-17 |
| JP2023516461A (ja) | 2023-04-19 |
| IT202000005011A1 (it) | 2021-09-09 |
| EP4117710A1 (en) | 2023-01-18 |
| BR112022017243A2 (pt) | 2022-10-18 |
| CA3174733A1 (en) | 2021-09-16 |
| US20230080695A1 (en) | 2023-03-16 |
| IL295528A (en) | 2022-10-01 |
| AU2021235546A1 (en) | 2022-09-08 |
| MX2022010874A (es) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017308A2 (pt) | Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral | |
| BR112019025381A2 (pt) | Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal | |
| BR112016026556A8 (pt) | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| CL2016000240A1 (es) | Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal. | |
| CL2015003120A1 (es) | Cepas bacterianas que poseen actividad antimicrobiana y composiciones de control biológico que las contienen | |
| BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
| BR112012008962A2 (pt) | derivados espiro-condensados de ciclohexano como inibidores de hsl úteis para o tratamento de diabetes | |
| BR112013002296A2 (pt) | composição farmacêutica e respectivo uso e método para tratar doença infecciosa | |
| AR083366A1 (es) | Formulaciones para el tratamiento de las afecciones de las vias aereas superiores | |
| BR112014018421A8 (pt) | Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas | |
| Lévesque et al. | Actinobacillus pleuropneumoniae possesses an antiviral activity against porcine reproductive and respiratory syndrome virus | |
| ECSP20084373A (es) | Tiofencarboxamidas sustituidas y análogos de las mismas | |
| BR112014021065A2 (pt) | Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor | |
| BR112022017240A2 (pt) | Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório | |
| MX2023002233A (es) | Compuestos fosfolipidos y usos de estos. | |
| BR112019008810A2 (pt) | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer | |
| PE20090653A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc | |
| BR112021019845A2 (pt) | Composições de vírus inativado e formulações de vacina contra zika | |
| MX2020012543A (es) | Diltiazem para usarse en el tratamiento de infecciones microbianas. | |
| AR106057A1 (es) | Composición con efecto antiviral, composición farmacéutica | |
| BR112022021423A2 (pt) | Uso de proteína surfactante d para tratar infecções virais | |
| BR112016012435A2 (pt) | Vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 | |
| BR112021006388A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero | |
| BR112023017274A2 (pt) | Vacina contra metapneumovírus humano |